P2Y12 receptor inhibitors in patients with non-STelevation acute coronary syndrome in the real world: Use, patient selection, and outcomes from contemporary European registries

European Heart Journal - Cardiovascular Pharmacotherapy

Volumn 2, Issue 4, 2016, Pages 229-243

  Zeymer, Uwe ^a   Widimsky, Petr ^b   Danchin, Nicolas ^c   Lettino, Maddalena ^d   Bardaji, Alfredo ^e   Barrabes, Jose A ^f   Cequier, Angel ^g   Claeys, Marc J ^h   De Luca, Leonardo ⁱ   Dörler, Jakob ^j   Erlinge, David ^k   Erne, Paul ^l   Goldstein, Patrick ^m   Koul, Sasha M ^k   Lemesle, Gilles ^m   Lüscher, Thomas F ⁿ   Matter, Christian M ⁿ   Montalescot, Gilles ^o   Radovanovic, Dragana ^l   Sendón, Jose Lopez ^p   Tousek, Petr ^b   Weidinger, Franz ^q   Weston, Clive F M ^r   Zaman, Azfar ^s   Andell, Pontus ^k   Li, Jin ⁿ   Wouter Jukema, J ^t   more..

^a KLINIKUM LUDWIGSHAFEN   (Germany)

^b CHARLES UNIVERSITY   (Czech Republic)

^c HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^d HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^e HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

^f HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^g HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^h ANTWERP UNIVERSITY HOSPITAL   (Belgium)

ⁱ EUROPEAN HOSPITAL   (Italy)

^j INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^k LUND UNIVERSITY   (Sweden)

^l UNIVERSITY OF ZURICH   (Switzerland)

^m LILLE UNIVERSITY HOSPITAL   (France)

ⁿ UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^o SORBONNE UNIVERSITÉ   (France)

^p HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^q Hospital Rudolfstiftung   (Austria)

^r SWANSEA UNIVERSITY   (United Kingdom)

^s NEWCASTLE UNIVERSITY   (United Kingdom)

^t LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

more..

Author keywords

Acute coronary syndromes; Antiplatelets; Clopidogrel; Non ST segment elevation; Observational; P2Y12 receptor inhibitors; Prasugrel; Ticagrelor

Indexed keywords

CLOPIDOGREL; PRASUGREL; PURINERGIC P2Y RECEPTOR ANTAGONIST; PURINERGIC P2Y12 RECEPTOR ANTAGONIST; TICAGRELOR; UNCLASSIFIED DRUG; ANTITHROMBOCYTIC AGENT; PURINERGIC P2Y12 RECEPTOR;

AGED; ARTICLE; BLEEDING; BRAIN ISCHEMIA; CAUSE OF DEATH; DRUG EFFICACY; DRUG SAFETY; DRUG USE; EUROPEAN; FEMALE; HOSPITAL MORTALITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY RATE; NON ST SEGMENT ELEVATION ACUTE CORONARY SYNDROME; PATIENT SELECTION; PRIORITY JOURNAL; REGISTER; SYSTEMATIC REVIEW; TREATMENT OUTCOME; ACUTE CORONARY SYNDROME; ADULT; CHEMICALLY INDUCED; COMBINATION DRUG THERAPY; EUROPE; ISCHEMIA; MIDDLE AGED; MORTALITY; VERY ELDERLY;

ACUTE CORONARY SYNDROME; ADULT; AGED; AGED, 80 AND OVER; DRUG THERAPY, COMBINATION; EUROPE; FEMALE; HEMORRHAGE; HUMANS; ISCHEMIA; MALE; MIDDLE AGED; PATIENT SELECTION; PLATELET AGGREGATION INHIBITORS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RECEPTORS, PURINERGIC P2Y12; REGISTRIES; TREATMENT OUTCOME;

EID: 85019913127     PISSN: 20556837     EISSN: 20556845     Source Type: Journal    
DOI: 10.1093/ehjcvp/pvw005     Document Type: Article

References (13)

1. Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, Bax JJ, Borger MA, Brotons C, Chew DP, Gencer B, Hasenfuss G, Kjeldsen K, Lancellotti P, Landmesser U, Mehilli J, Mukherjee D, Storey RF, Windecker S. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J 2016;37:267-315.
2. Olivari Z, Steffenino G, Savonitto S, Chiarella F, Chinaglia A, Lucci D, Maggioni AP, Pirelli S, Scherillo M, Scorcu G, Tricoci P, Urbinati S. The management of acute myocardial infarction in the cardiological intensive care units in Italy: The BLITZ 4 Qualita campaign for performance measurement and quality improvement. Eur Heart J Acute Cardiovasc Care 2012;1:143-152.
3. Jukema JW, Lettino M, WidimskýP, Danchin N, Bardaji A, Barrabes JA, Cequier A, Claeys MJ, De Luca L, Dörler J, Erlinge D, Erne P, Goldstein P, Koul SM, Lemesle G, Lüscher TF, Matter CM, Montalescot G, Radovanovic D, Lopez Sendón J, Tousek P, Weidinger F, Weston CFM, Zaman A, Zeymer U. Contemporary registries on P2Y12 inhibitors in patients with acute coronary syndromes in Europe: overview and methodological considerations. Eur Heart J Cardiovasc Pharmacother 2015;1: 232-244.
4. Danchin NL, Maddalena L, Zeymer U, WidimskýP, Danchin N, Bardaji A, Barrabes JA, Cequier A, Claeys MJ, De Luca L, Dörler J, Erlinge D, Erne P, Goldstein P, Koul SM, Lemesle G, Lüscher TF, Matter CM, Montalescot G, Radovanovic D, Lopez Sendón J, Tousek P, Weidinger F, Weston CFM, Zaman A, Andell P, Li J, Jukema JW. Use, patient selection and outcomes of P2Y12 receptor inhibitor treatment in patients with STEMI based on contemporary
5. Bovill EG, Terrin ML, Stump DC, Berke AD, Frederick M, Collen D, Feit F, Gore JM, Hillis LD, Lambrew CT, Leiboff R, Mann KG, Markis JE, Pratt CM, Sharkey SW, Sopko G, Tracy RP, Chesebro JH. Hemorrhagic events during therapy with recombinant tissue-Type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial. Ann Intern Med 1991;115:256-265.
6. Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, Kaul S, Wiviott SD, Menon V, Nikolsky E, Serebruany V, Valgimigli M, Vranckx P, Taggart D, Sabik JF, Cutlip DE, Krucoff MW, Ohman EM, Steg PG, White H. Standardized bleeding definitions for cardiovascular clinical trials: A consensus report from the Bleeding Academic Research Consortium. Circulation 2011;123: 2736-2747.
7. Sabatine MS, Morrow DA, Giugliano RP, Burton PB, Murphy SA, McCabe CH, Gibson CM, Braunwald E. Association of hemoglobin levels with clinical outcomes in acute coronary syndromes. Circulation 2005;111:2042-2049.
8. Antman EM, Cohen M, Bernink PJ, McCabe CH, Horacek T, Papuchis G, Mautner B, Corbalan R, Radley D, Braunwald E. The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. JAMA 2000;284:835-842.
9. Granger CB, Goldberg RJ, Dabbous O, Pieper KS, Eagle KA, Cannon CP, Van De Werf F, Avezum A, Goodman SG, Flather MD, Fox KA. Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med 2003;163: 2345-2353.
10. European Medicines Agency (EMA). Brillque(R). Ticagrelor summary of product characteristics and package leaflet. http://www.emea.europa.eu (28 January 2016).
11. Efient(R) summary of product characteristics. http://www.ema.europa.eu (28 January 2015).
12. Montalescot G, Collet JP, Ecollan P, Bolognese L, Ten Berg J, Dudek D, Hamm C, Widimsky P, Tanguay JF, Goldstein P, Brown E, Miller DL, LeNarz L, Vicaut E. Effect of prasugrel pre-Treatment strategy in patients undergoing percutaneous coronary intervention for NSTEMI: The ACCOAST-PCI study. J Am Coll Cardiol 2014;64: 2563-2571.
13. Quinlan DJ, Eikelboom JW, Goodman SG, Welsh RC, Fitchett DH, Theroux P, Mehta SR. Implications of variability in definition and reporting of major bleeding in randomized trials of oral P2Y12 inhibitors for acute coronary syndromes. Eur Heart J 2011;32:2256-2265. 244-255